Clinical Trial Update: SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating SDX-105 in combination with Rituxan for relapsed indolent or mantle cell Non-Hodgkin's Lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Rituxan (rituximab)
• SDX-105

Snippet

Sponsor: Cephalon | Conditions: Non-Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED